Krka

Krka sales, profit at all-time high in 2022

The Slovenian pharma group Krka generated record high sales revenue and profit last year. Revenue was up by 10% to €1.7 billion and net profit rose by 17% to €361 million, according to unaudited results released by the company on 26 January.

Krka saw sales going up in most of its key markets and across all product and service segments.

Downbeat year for Slovenian stocks

The SBI TOP benchmark index on the Ljubljana Stock Exchange lost nearly 16% in 2022, after having risen by almost 40% the year before, show figures released by the stock exchange operator Ljubljanska Borza.

All the big-cap stocks were down with drug maker Krka losing nearly a fifth of its value in a year, NLB bank down by 18%, and energy group Petrol losing 21%.

Pharma group Krka posts record January-June sales, profit

Novo Mesto/Otočec – Pharmaceutical group Krka posted a net profit of EUR 177.4 million for the first half of the year, up 11% on the back of sales that reached EUR 808.6 million, up 1% over the same period last year, CEO Jože Colarič said at the company’s annual general meeting in Otočec on Thursday.